Drugs / MANP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03781739 | Aug 2017 → Nov 2019 | hypertensive disorder, metabolic syndrome X | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03781739 ↗ |
| Action | Activate | “activates the particulate guanylyl cyclase A receptor” PMID 38362338 ↗ Nov 2023 |
| Modality | Peptide | “M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog” PMID 38362338 ↗ Nov 2023 |
| Route | Subcutaneous | “a single subcutaneous injection of M-atrial natriuretic peptide” PMID 38362338 ↗ Nov 2023 |